Shares in Boston Scientific (NYSE:BSX) slid nearly 4% on news that the rates of cardiac death in patients implanted with its Acurate Neo heart valve were significantly higher than those in patients who received Medtronic’s (NYSE:MDT) CoreValve Evolut. The head-to-head SCOPE II study, presented today at TCT Connect, the 32nd annual scientific symposium of the Cardiovascular Research Foundation, […]
TCT 2020
Abbott touts Xience DES study results
A pair of studies of Abbott’s Xience drug-eluting stent showed no difference between shorter courses of treatment with dual antiplatelet therapy (DAPT) compared with 12 months of DAPT following implantation of the XIENCE drug-eluting stent (DES) in patients who are at a high risk of bleeding. Abbott presented the late-breaking data today at TCT Connect, […]
Abiomed touts latest Impella trial results
Abiomed (NSDQ:ABMD) today announced interim results of a study that found high-risk patients had better outcomes after implantation with its Impella CP heart pump. Data from the PROTECT III FDA post-approval study of Impella 2.5 and Impella CP in high-risk percutaneous coronary intervention (PCI) patients showed reduced rates of MACCE — a composite of death, stroke, […]
